A next generation BCG vaccine moves forward
- PMID: 35772448
- DOI: 10.1016/S1473-3099(22)00287-0
A next generation BCG vaccine moves forward
Conflict of interest statement
HMD was previously funded by the TBVAC2020 Consortium, which was funded by the EU Horizon 2020 programme, the Bill & Melinda Gates funded GC6–74 and GC6–2013 consortia, the EU FP7 funded Concurrent Tuberculosis and Diabetes Mellitus Consortium consortium, and the European and Developing Countries Clinical Trials Partnership funded AE-TBC and ScreenTB consortia, and is a current member of the EDCTP funded TriageTB consortium, which include several of the authors of the VPM1002 study but has had no role in the development of this vaccine.
Comment on
-
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.Lancet Infect Dis. 2022 Oct;22(10):1472-1483. doi: 10.1016/S1473-3099(22)00222-5. Epub 2022 Jun 27. Lancet Infect Dis. 2022. PMID: 35772447 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
